×
About 564 results

ALLMedicine Waldenstrom Macroglobulinemia Center

Research & Reviews  257 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicul...
https://clinicaltrials.gov/ct2/show/NCT01381692

May 4th, 2020 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of temsirolimus in combination with bortezomib, rituximab, dexamethasone in patients with relapsed Waldenstrom's macroglobulinemia and relapsed/refractory mantle cell, follicular...

An unusual case of cutaneous Waldenstrom macroglobulinemia with the MYD88 L265P mutation.
https://doi.org/10.1111/cup.13722
Journal of Cutaneous Pathology; Minzenmayer A, Miranda RN et. al.

Apr 26th, 2020 - Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma with bone marrow involvement and a monoclonal IgM gammopathy. Infiltration of the skin by neoplastic cells is very rare, and it can be difficult to distinguish from marginal zone lympho...

Waldenstrom Macroglobulinemia Treatment Protocols 
https://emedicine.medscape.com/article/2057687-overview

Apr 19th, 2020 - Treatment Protocols Numerous single and multiagent chemotherapeutic approaches are used in the treatment of Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL); however, none is considered the "standard of care." There is a paucity...

see more →

Guidelines  2 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

see more →

Clinicaltrials.gov  279 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicul...
https://clinicaltrials.gov/ct2/show/NCT01381692

May 4th, 2020 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of temsirolimus in combination with bortezomib, rituximab, dexamethasone in patients with relapsed Waldenstrom's macroglobulinemia and relapsed/refractory mantle cell, follicular...

An unusual case of cutaneous Waldenstrom macroglobulinemia with the MYD88 L265P mutation.
https://doi.org/10.1111/cup.13722
Journal of Cutaneous Pathology; Minzenmayer A, Miranda RN et. al.

Apr 26th, 2020 - Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma with bone marrow involvement and a monoclonal IgM gammopathy. Infiltration of the skin by neoplastic cells is very rare, and it can be difficult to distinguish from marginal zone lympho...

Waldenstrom Macroglobulinemia Treatment Protocols 
https://emedicine.medscape.com/article/2057687-overview

Apr 19th, 2020 - Treatment Protocols Numerous single and multiagent chemotherapeutic approaches are used in the treatment of Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL); however, none is considered the "standard of care." There is a paucity...

see more →

News  17 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

Change the 'Asymptomatic' Label for Rare Lymphoma Status
https://www.medscape.com/viewarticle/919696

Oct 9th, 2019 - Patients in the early stages of Waldenstrom macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma, are usually followed with observation rather than offered treatment and are labeled "asymptomatic." But this label is inaccurate because many ...

Waldenstrom Macroglobulinemia Clinical Practice Guidelines (2018)
https://www.medscape.com/viewarticle/905623

Nov 29th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO).[1] Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on...

Combo treatment under review for Waldenstrom macroglobulinemia
https://www.mdedge.com/hematologynews/nhlhub/article/168936/indolent-lymphoma/combo-treatment-under-review-waldenstrom
Mary Ellen Schneider

Jun 26th, 2018 - Ibrutinib in combination with rituximab as a treatment for Waldenström macroglobulinemia (WM) is under priority review by the Food and Drug Administration. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is already approved as a single agent for.

see more →

Patient Education  9 results see all →